Immunotherapy of metastatic renal cell carcinoma: report of 28 cases.
- Author:
Hui-jun WANG
1
;
Hai WANG
;
Han-zhong LI
;
Bing-bing SHI
;
Zong-lu SONG
Author Information
- Publication Type:Clinical Trial
- MeSH: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Renal Cell; therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Floxuridine; administration & dosage; Humans; Immunotherapy; Injections, Subcutaneous; Interferons; administration & dosage; Interleukin-2; administration & dosage; Kidney Neoplasms; therapy; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome
- From: Chinese Journal of Surgery 2004;42(4):205-206
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the efficacy of IL-2, IFN and Furtulon in patients with metastatic renal cell carcinoma.
METHODSDuring the induction phase of the treatment of 28 patients, which lasted 3 months, IL-2 and IFN were administered subcutaneously three times a week at doses of 5 - 20 MU/m(2) and 6 - 9 MU/m(2), Furtulon was administered at doses of 800 - 1,200 mg daily by oral during 28 days a month.
RESULTSThe response rate was 46.4%, including 4 complete response (CR), 9 presented with partial response (PR).
CONCLUSIONThe three-drugs combination described in this study demonstrates activity. Based on the present data, combined biochemotherapy may be a promising new approach to the therapy of the metastatic renal cell carcinoma.
